Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Background IMGN901 is a CD56-targeting antibody-drug conjugate designed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1 study investigated the safety, tolerability, pharmacokinetics, and preliminary activity of IMGN901 in patients with CD56-expressing solid tumors. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manisha H., Lorigan, Paul, O’Brien, Mary E. R., Fossella, Frank V., Moore, Kathleen N., Bhatia, Shailender, Kirby, Maurice, Woll, Penella J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859861/
https://www.ncbi.nlm.nih.gov/pubmed/26961907
http://dx.doi.org/10.1007/s10637-016-0336-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859861/
https://www.ncbi.nlm.nih.gov/pubmed/26961907
http://dx.doi.org/10.1007/s10637-016-0336-9

Ejemplares similares